---
title: "Allakos (ALLK.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALLK.US/overview.md"
symbol: "ALLK.US"
name: "Allakos"
parent: "https://longbridge.com/en/quote/ALLK.US.md"
datetime: "2026-04-05T01:05:59.042Z"
locales:
  - [en](https://longbridge.com/en/quote/ALLK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALLK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALLK.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ALLK.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ALLK.US/overview.md)


# Allakos (ALLK.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Company Profile

Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**